Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2014

View Archived Issues

Development of novel potent oxytocin receptor agonists to correct aberrant preterm lactation

Burnet Institute and Artes Biotechnology to develop new type of malaria vaccine

Pfizer reflects on achievements of second quarter 2014

AstraZeneca to acquire Almirall's respiratory business

AstraZeneca and Kyowa Hakko Kirin form clinical immuno-oncology collaboration

Roche and AmorChem collaborate in myotonic muscular dystrophy 1

Zealand Pharma and Boehringer Ingelheim collaborate in cardiometabolic disease

Immune Pharmaceuticals initiates phase II trial of bertilimumab in bullous pemphigoid

Novel Nrf2 pathway activator tested in animal model for treatment of ischemia-reperfusion injury

Piramal Enterprises designs novel agents for cancer

New compounds for bacterial infections disclosed by Actelion Pharmaceuticals

Promising preclinical results with anti-CD154 antibody BMS-986004 in kidney transplant models

Merck KGaA patents new piperidinylcarbazole derivatives for malaria

Gilead Sciences synthesizes novel antiretrovirals

Aurigene Discovery Technologies divulges novel BTK inhibitors

Phase II efficacy, safety and favorable pharmacometrics of TOL-101

Stivarga approved in the E.U. for gastrointestinal stromal tumors

Regeneron and Sanofi report topline data from nine phase III trials of alirocumab

Baxter divests commercial vaccines business to Pfizer

Incyte and Genzyme to evaluate combination of two novel cancer immunotherapies

New start-up Emulate to commercialize Wyss Institute's Organs-on-Chips technology

Amgen reveals milestones of second quarter 2014

Glide Pharmaceutical licenses rights from FScan to prostate cancer diagnostic technology

Angelini to commercialize dalbavancin in select European countries

Evotec identifies novel targets in Alzheimer's disease collaboration with Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...